Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide

Diabetes

Volumn 44, Issue 1, 1995, Pages 16-19

  Kolligs, Frank ^a   Fehmann, Hans C ^a   Göke, Rüdiger ^a   Göke, Burkhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; DIABETES MELLITUS; GLUCOSE METABOLISM; INSULIN RELEASE; MALE; NONHUMAN; PANCREAS SECRETION; PRIORITY JOURNAL; RAT;

EID: 0028883257     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.44.1.16     Document Type: Article

References (26)

1. McIntyre N, Holdsworth CD, Turner DS: New interpretation of oral glucose tolerance. Lancet ii:20-21, 1964
2. Perley MJ, Kipnis DM: Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 46:1954-1962, 1967
3. Zunz E, La Barre J: Contributions à l'étude des variations physiologiques de la secretion interne du pancreas: relations entre les secretions externe et interne du pancreas. Arch Int Physiol Biochim 31:20-44, 1929
4. Creutzfeldt W: The incretin concept today. Diabetologia 16:75-85, 1979
5. Ensinck JW, D'Alessio DA: The enteroinsulinar axis revisited: a novel role for an incretin. N Engl J Med 326:1352-1353, 1992
6. Brown JC, Dryburgh JR, Ross SA, Dupre J: Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res 31:487-532, 1975
7. Brown JC, Otte SC: Gastrointestinal hormones and the control of insulin secretion. Diabetes 27:782-787, 1978
8. Ebert R, Illmer K, Creutzfeldt W: Release of gastric inhibitory polypeptide (GIF) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP-antiserum in rats. Gastroenterology 76:515-523, 1979
9. Ebert R: Gut signals for islet hormone release. Eur J Clin Invest 20 (Suppl. 1):20-26, 1990
10. Nauck M, Härter S, Ebert R, Creutzfeldt W: Effects of four orally administered analogues of prostaglandin E1 and E2 on glucose tolerance and on the secretion of pancreatic and gastrointestinal hormones in man. Eur J Clin Invest 19:298-305, 1989
11. Göke R, Fehmann HC, Göke B: Glucagon-like peptide 1 (7-36) amide is a new incretin/enterogastrone candidate. Eur J Clin Invest 21:135-144, 1991
12. Fehmann HC, Göke R, Göke B: At the cutting edge of glucagon-like peptide 1 (7-37)/(7-36) amide is a new incretin. Mol Cell Endocrinol 85:C39-C44, 1992
13. Holz GG, Kühtreiber WM, Habener JF: Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide 1 (7-37). Nature 361:362-365, 1993
14. Gutniak M, Orskov C, Hoist JJ, Ahren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide 1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
15. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 (7-36) amide but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 91:301-307, 1993
16. Rai A, Singh G, Raffaniello R, Eng J, Raufman JR: Actions of Helodermatidae venom peptides and mammalian glucagon-like peptides on gastric chief cells. Am J Physiol 265:G118-G125, 1993
17. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B: Exendin-4 is a high potency agonist and truncated exendin (9-39) amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin secreting cells. J Biol Chem 268:19650-19655, 1993
18. Göke B, Elsebach K, Hausmann W, Schaar M, Arnold R, Adler G: Endocrine pancreatic morphology and function in exocrine insufficiency in rats. Am J Physiol 253:G139-G145, 1987
19. Göke R, Conlon JM: Receptors for glucagon-like peptide 1 (7-36) amide on rat insulinoma-derived cells. J Endocrinol 116:357-362, 1988
20. Göke R, Wagner B, Fehmann HC, Göke B: Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide 1 (7-36) amide on the rat pancreas. Res Exp Med 193:97-103, 1993
21. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Göke B: Glucagon-like peptide 1 (7-36) amide cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22:283-291, 1992
22. Fehmann HC, Jiang J, Schweinfurth J, Wheeler MB, Boyd AE, Göke B: Stable expression of the rat GLP-1 receptor in CHO-cells: activation and binding characteristics utilizing GLP-1(7-36)amide, oxyntomodulin, exendin-4, and exendin (9-39) amide. Peptides 15:453-456, 1994
23. Eng J, Guttermann V, Nicolis C: Exendin (9-39) amide inhibits the insulin secretagogue activity of exendin-4 and GLP-1 but enhances that of glucagon in the dog (Abstract). Digestion 54:354, 1993
24. Roberge JN, Brubaker PL: Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 133:233-240, 1993
25. Herrmann C, Vöge A, Göke B: Regulation of glucagon-like peptide 1 release from the isolated perfused rat ileum by nutrients, peptides and neuromediators (Abstract). Digestion 54:367, 1993
26. Nauck M, Bartels E, Orskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 (7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917, 1993